UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
We are proud to be the first company outside the US to have started the regulatory approval and commercialization process for Jelmyto, demonstrating Israel's importance in geographic expansion.
- We are proud to be the first company outside the US to have started the regulatory approval and commercialization process for Jelmyto, demonstrating Israel's importance in geographic expansion.
- I am confident that our well-established expertise and heritage of collaboration with innovative biopharmaceutical companies will make Jelmyto a success in Israel.
- UroGen is committed to bringing the promise of Jelmyto to as many patients as possible, as quickly as feasible.
- JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005968/en/